JPRN-UMIN000007950已完成2 期
Efficacy of ibritumomab tiuxetan (Zevalin) following remission induction therapy for relapse of follicular lymphoma - Ibritumomab tiuxetan (Zevalin) for relapse of follicular lymphoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
Entry completed
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with uncontrollable infection. 2) Intolerable allergy for rituximab or drugs derived from murine proteins. 3) Previous history of allogeneic stem cell transplant. 4) Pregnant (or possibly pregnant) patient 5) Patients receiving anti-coagulants or anti-thrombotic agents. 6) Patients with hemorrhagic symptoms. 7) Patients receiving external radiation for more than 25% of total bone marrow. 8) Patients planning to undergo rituximab maintenance therapy.
研究者
相似试验
进行中（未招募）
1 期
Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma. - ZEUSEUCTR2006-006808-11-ITAZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
已完成
4 期
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's LymphomaLymphoma, Non-HodgkinLymphoma, Low-GradeNCT00168727Biogen12
进行中（未招募）
不适用
90Y ibritumomab tiuxetan (Zevalin®) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) - ZENOEUCTR2007-004289-42-GRational and Kapodistrian University of Athens40
已完成
2 期
Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular LymphomaFollicular LymphomaNCT01493479The Christie NHS Foundation Trust76
终止
2 期
Ibritumomab Tiuxetan (Zevalin)+ Rituximab MaintenanceNon-Hodgkin's LymphomaNCT00582166University of Wisconsin, Madison18